Review article

Tuberculosis in Patients With Systemic Lupus Erythematosus: Spain’s Situation

María del Mar Arenas Miras, a,∗ Carmen Hidalgo Tenorio, b Juan Jiménez Alonso a

a Servicio de Medicina Interna, Hospital Universitario Virgen de las Nieves, Granada, Spain
b Sección de Infecciosas, Hospital Universitario Virgen de las Nieves, Granada, Spain

ARTICLE INFO

Article history:
Received 15 March 2012
Accepted 21 June 2012
Available online 8 December 2012

Keywords:
Systemic lupus erythematosus
Tuberculosis
Human immunodeficiency virus infection

ABSTRACT

There has recently been an increase in the incidence of patients with systemic lupus erythematosus (SLE) mainly due to earlier diagnosis, and increased survival. Tuberculosis in our country is one of the most prevalent infectious diseases, and one of the underlying causes would be HIV infection and increased immigration from areas with high tuberculosis prevalence; this phenomenon is truly important in patients with autoimmune diseases, as clinical presentation, severity and prognosis of tuberculosis are often different to that of immunocompetent patients. Studies of tuberculosis in patients with SLE are scarce and inconclusive, with many doubts existing about the performance or non-tuberculous prophylaxis in this population and the absence of a protocol due to lack of conclusive studies. New techniques for diagnosis of tuberculosis (IGRAs) may be useful in this population due to higher sensitivity than Mantoux, helping avoid false negatives.

© 2012 Elsevier España, S.L. All rights reserved.

La infección tuberculosa en pacientes con lupus eritematoso sistémico: situación en España

RESUMEN

En la actualidad se ha detectado un aumento en la incidencia de pacientes con lupus eritematoso sistémico (LES) debido fundamentalmente a un diagnóstico más precoz, e incremento en la supervivencia de estos. La tuberculosis en nuestro país es una de las enfermedades infecciosas más prevalentes; como causa subyacente, entre otras, estaría la infección por VIH y el aumento de inmigrantes procedentes de áreas con alta prevalencia tuberculosa; este fenómeno es verdaderamente importante en los pacientes con enfermedades autoinmunes, ya que la presentación clínica, intensidad y pronóstico de la tuberculosis suelen ser diferentes a los de los pacientes inmunocompetentes. Los estudios sobre tuberculosis en paciente con LES son escasos y poco concluyentes, habiendo hoy en día muchas dudas sobre la realización o no de profilaxis tuberculosa en esta población y sin haberse establecido aún un protocolo de actuación por falta de estudios concluyentes al respecto. Las nuevas técnicas de diagnóstico de infección tuberculosa (IGRA) podrían ser útiles en esta población debido a su mayor sensibilidad respecto al Mantoux, evitando también los falsos negativos del mismo.

© 2012 Elsevier España, S.L. Todos los derechos reservados.

Tuberculosis is the most common infectious disease in the world, estimated at about 8 million new cases per year, with 12 million existing cases, involving a total of 20 million cases annually.1 Consequently, the general population is more exposed to the TB bacilli, something particularly disturbing in immunocompromised persons, including patients with systemic lupus erythematosus (SLE).2 and this phenomenon is exacerbated in developing countries that have detected a high incidence of extrapulmonary tuberculosis with high mortality figures.

In Spain the actual incidence of tuberculosis in the general population is not well known due to, among other causes, underreporting and underdiagnosis, especially among the elderly population.3 In recent years there has been a decline in the number of reported cases, reaching 5795 in 2007, although it is estimated that approximately 30%–40% of cases are not reported, so the numbers could be significantly higher.4 According to data from the National Epidemiological Surveillance Network, the total number of cases reported in 2009 was 7652, equivalent to a crude incidence rate of 16.96 cases per 100,000 persons. Communities with higher


¢ Corresponding author.

E-mail address: mmarenas@hotmail.com (M.M. Arenas Miras).

2173-5743/5 – see front matter © 2012 Elsevier España, S.L. All rights reserved.
overall rates were Ceuta, Galicia, La Rioja and Melilla, although the number of reported cases include Catalonia, Andalusia, and Madrid.\

Currently, the main causes of death in patients with lupus are cardiovascular disorders and infections, the latter predominating in several series. The administration of steroids and cyclophosphamide are 2 of the main risk factors in the development of infection. Differential diagnosis between infection and lupus flares is sometimes difficult, but essential because delays in treatment of both processes are associated with increased mortality. Moreover, TB simulates some of the findings of autoimmune diseases such as joint pain/arthritus, rash or presence of autoantibodies, which poses a problem for the diagnosis of this disease.

In patients with SLE there are immunologic and genetic alterations that predispose them to the development of infections. Among those described are a deficit in complement, functional asplenia, impaired phagocytic system or functional deficits in the activity of T cells, with reduced cytotoxic T cells and alterations in the function of suppressor T cells, determining increased susceptibility to infections by mycobacteria. Added to this, the use of immunosuppressive agents such as azathioprine, cyclophosphamide or mycophenolate produces decreased T and B lymphocytes counts, and the widespread use of corticosteroids blocks T cell proliferation, cytotoxic T cells, microbicidal activity and antigen-specific immune response, producing a significant impairment of cellular immunity, and increased risk of infection by intracellular pathogens such as Mycobacterium tuberculosis, viruses of the herpes family and Pneumocystis jirovecii among other pathogens such as Listeria spp. and Nocardia spp.

In countries where TB is endemic there have been numerous studies in patients with lupus. However, in Spain these are scarce and inconclusive.

In a retrospective study comprising 390 patients with SLE from the Philippines, had active tuberculosis, and of these, 74% had only pulmonary involvement; it also found that patients with disseminated infection had a higher lupus activity index and more aggressive disease, regardless of the corticosteroid dose they were receiving at the time of diagnosis. In another retrospective study that included 283 SLE patients and 284 with rheumatoid arthritis from Korea, it was found that the most common form of involvement was pulmonary tuberculosis and lupus, mainly in patients with higher doses of corticosteroids. Alongside this, a greater percentage of extrapulmonary tuberculosis was described in lupus patients than in the general population, up to 45% of cases by one of the published series, and the main risk factor was higher daily or cumulative doses of corticosteroids during the year before diagnosis, more often for arthritis and renal involvement. These findings were similar to those described by Tam et al., who conducted a case-control study in Hong Kong consisting of 526 patients with SLE an who provided analysis of the different risk factors involved in the development of active tuberculosis. In this study, a univariate analysis, patients with SLE and cerebral involvement had higher rates of tuberculosis, nephritis, vasculitis, cumulative dose of corticosteroids and intravenous methylprednisolone pulses relative to the control group. In the multivariate analysis, the presence of nephritis and the cumulative dose of corticosteroids were independent risk factors for developing the disease. They also found an increase of extrapulmonary tuberculosis, which together with the military for, was the most common presentation in patients (67%). The other risk factor independently associated with the occurrence of tuberculosis in patients with SLE was pleuritis.

As for Spanish studies on tuberculosis in patients with lupus, there have been three types so far. The first was a retrospective study which consisted of patients with lupus treated in the Systemic Autoimmune Diseases Unit of the Hospital de Cruces in the Basque Country between 1994 and 2003. In this, the incidence of active tuberculosis in patients with SLE (187 cases per 100,000) was compared with the population of the area (20–45 cases per 100,000), which turned out to be much lower than that of patients with lupus, and no predictor for the development of tuberculosis was identified among their patients. The second, also retrospective, was held at the Rheumatology Service, Hospital Clinico San Carlos in Madrid, and was composed of patients diagnosed with autoimmune disease and tuberculosis treated at the Unit. They found an incidence rate of tuberculosis in patients with autoimmune diseases of 153 cases per 100,000 patient-years, which increased to 645 cases/100,000 patient years when analyzing patients with SLE and vasculitis; in that year the incidence of tuberculosis in the Autonomous Community of Madrid was 26 cases per 100,000 population per year, concluding that extrapulmonary tuberculosis was more common in patients with autoimmune disorders in the general population. Tuberculosis patients were older and had no other risk factors for developing the disease. The third study was made up of a cohort of 789 (January 1989–January 2009) SLE patients treated in the Autoimmune Diseases Unit of the Hospital Universitario Virgen del Rocio de Sevilla, comparing patients with and without tuberculosis. They found 13 cases, with 61% having extrapulmonary forms. Overall mortality attributed to this infection was 30.8% and the frequency of tuberculosis was higher than that in the general population. However, although patients treated with higher doses of corticosteroids had more severe forms of the disease, no statistically significant differences were seen with other immunosuppressive therapies or greater frequency of renal involvement.

The problem of the different epidemiological studies that have been conducted so far is that most are retrospective, introduce selection bias, and do not take into account socio-economic conditions.

With respect to the diagnosis and treatment of latent tuberculosis, general recommendations, according to the American Thoracic Society, consider the need for treatment with isoniazid for 9 months when the skin reaction (TST) is ≥ 10 mm in patients with diseases that increase the risk of developing the infection, and ≥ 5 mm in all those receiving more than 15 mg of prednisone daily or its equivalent. It also recommended annual TST for all persons whose social condition merited it or presented an increased risk of active tuberculosis during certain time periods or in the foreseeable future. This risk is well established for certain groups of patients, but not known exactly in lupus patients (Table 1).

In Spain, the Society of Clinical Microbiology and Infectious Diseases, along with the Society of Pneumology and Thoracic Surgery (SEPAR), recently published a consensus document on recommendations for diagnosis, treatment and prevention of tuberculosis. This document contains the instructions for the TST (Table 2), in which patients with prolonged immunosuppressive therapy are included, and with causes associated with false negatives, such as prolonged corticosteroid therapy (≥ 15 mg of prednisone for

<table>
<thead>
<tr>
<th>Clinical condition</th>
<th>Relative risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV/AIDS</td>
<td>100–500</td>
</tr>
<tr>
<td>Sarcoidosis</td>
<td>30</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>2.0–4.1</td>
</tr>
<tr>
<td>Chronic renal failure/hemodialysis</td>
<td>10.0–25.3</td>
</tr>
<tr>
<td>Gastroctomy</td>
<td>2–5</td>
</tr>
<tr>
<td>Yeyounoide bypass</td>
<td>27–63</td>
</tr>
<tr>
<td>Solid organ transplant</td>
<td></td>
</tr>
<tr>
<td>Renal</td>
<td>37</td>
</tr>
<tr>
<td>Cardiac</td>
<td>20–74</td>
</tr>
<tr>
<td>Carcinoma of the head or neck</td>
<td>16</td>
</tr>
</tbody>
</table>
more than one month), and any immunosuppressive chemothera-
py (Table 3).

Today, new tuberculosis diagnostic techniques are being intro-
duced into clinical practice guidelines from various societies,
but their role in the various risk groups is yet to be determined. They
are based on the detection of gamma interferon in the blood (inter-
feron gamma release assay [IGRA]), which is released in response
to in vitro stimulation of primed T-cells with specific antigens
of M. tuberculosis. There are currently two commercialized tests:
Quantiferon®-TB Gold In-Tube, using ELISA, and T-SPOT®,
TB, based on the ELISPOT24 technique. The concordance rate between
the two is high, but it seems that T-SPOT®, TB is more sensitive than
Quantiferon®-TB Gold In-Tube.25 At present, SEPAR recommends a
Mantoux test for diagnosis of tuberculosis infection in immuno-
compromised patients, and if negative, the performance of an
IGRA (to avoid false negatives due to immunosuppression). For SLE
patients, some studies have been published using Quantiferon®-
TB Gold in areas of high prevalence of tuberculosis.26,27 Their
authors have been struck by the high percentage of indeterminate
results of this technique with respect to the general population,
due to lymphocytopenia suffered by many of these patients and
the degree of disease activity, so they recommend interpreting the
results with caution. In Spain there are still no data.

Despite the recommendations, and that the incidence of
 tuberculosis in lupus appears to be higher than in the general
population,16–18 the relative risk of infectious reactivation has not
been formally established in these patients,11 and therefore the
use of isoniazid for treating latent tuberculosis in lupus patients is
not formalized. Regarding this issue, two studies have been pub-
lished in high TB prevalence areas, India28 and Hong Kong.29 The
first found a reduction in the prevalence of active tuberculosis in
lupus patients following administration of isoniazid, 11%–2%. In the
second there was no greater protection, which we believe was due
to the wrong design and methodology, since isoniazid was admin-
istered intermittently depending on the steroid dose received by
the patient.

In conclusion, we can say that tuberculosis is currently one of the
most common infectious problems worldwide, and it is especially
necessary to detect the latent phase in patients with autoimmune
diseases because of the risk of reactivation. Regarding patients with
SLE and tuberculosis in Spain, there is little data and it is all retro-
spective, so we need prospective studies on incidence and more
viable and diagnostic clinical trials to evaluate the risk/benefit of
treatment of latent infection.6,17,25

Ethical Considerations

Protection of Persons and Animals. No experiments were per-
formed on humans or animals.

Data Confidentiality. Patient data do not appear in this article.

Right to Privacy and Informed Consent. Authors obtained
informed consent from patients and/or subjects referred to in
this paper. These are in the hands of the corresponding author.

Conflict of Interest

The authors declare no conflict of interest.

References

1. World Health Organization. Global tuberculosis control-epidemiology, strategy,
3. Erdozain JC, Ruiz-Iturraza G, Eguibide MV, Martínez-Berriotxoa A, Aguirre
Incidence y características de la tuberculosis en pacientes con enfermedades
5. Ríos M, Monleón-Getino T. A graphical study of tuberculosis incidence and
6. Rodríguez E, Villarubia S, Díaz O, Hernández G, Tello O. Situación de la tubercu-
losis en España. Casos de tuberculosis declarados a la Red Nacional de Vigilancia
Barcelona: MRA Ediciones; 2002.
9. Kang I, Park SH. Infectious complications in SLE after immunosuppressive ther-
fections in systemic lupus erythematosus: a prospective and controlled study of
11. Fessler BJ. Infectious diseases in systemic lupus erythematosus: risk factors,
12. Victoria-Navarra ST, Díez EY, Arroyo CG, Torralba TP. Tuberculosis among Fil-
13. Park SH, Kan GI. Infectious complications in SLE after immunosuppressive ther-
FJ, Castillo Palma MJ, Sánchez Román J. Tuberculosis in una cohorte de pacientes